Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis.

Author: He HUANG ¹ ; Min CHEN ² ; Wenjuan WU ¹ ; Tianhui YANG ¹ ; Hao LIU ¹ ; Zhengwei ZHU ¹ ; Wenjun WANG ¹ ; Sen YANG ¹ ; Xian DING ³ ; Hui WANG ³ ; Yujun SHENG ¹ ; Yaohua ZHANG ⁴ ; Min LI ² ; Xuejun ZHANG ¹
Author Information

1. Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230031, China.
2. Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University, Suzhou Dushu Lake Hospital), Suzhou, Jiangsu 215125, China.
3. Ferry Institute of Dermatology, Hefei, Anhui 230000, China.
4. Department of Dermatology, Institute of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Publication Type:Letter
MeSH: Humans; East Asian People; Psoriasis/drug therapy*; Antibodies, Monoclonal, Humanized/therapeutic use*; Treatment Outcome; Severity of Illness Index
From: Chinese Medical Journal 2023;136(3):360-361
CountryChina
Language:English